2018-2019 Provincial Budget - IRICoR receives $12.3M from the MESI, a clear commitment from the government to life sciences
28 Mar, 2018, 13:33 ET
MONTREAL, March 28, 2018 /CNW Telbec/ - IRICoR is delighted by the government's show of support, in the amount of $12.3M, enabling it to carry out its research project maturation activities in oncology and in immunology for the purpose of establishing partnerships with industry.
"We are proud to be able to rely on this substantial assistance from the Government of Quebec, allowing us to support the efforts of investigators from Quebec, Canada and abroad by providing them with access to cutting-edge technology, thus translating their scientific innovations into therapeutic solutions that will benefit patients." said Nadine Beauger, Chief Executive Officer of IRICoR.
In close to 10 years of existence, IRICoR has already experienced great success: 3 companies created, 50 patent families generated, 80 project financings, 23 licensing agreements reached, and 4 active clinical trials.
IRICoR commends the support shown by the Government of Quebec for the research centres, which paves the way to international exposure of Quebec expertise in the development of therapeutic solutions for patients.
Click here to view the entire provincial budget
About the IRICoR (Institute for Research in Immunology and Cancer – Commercialization of Research)
As Université de Montréal's drug discovery and project maturation cluster, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC), with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR successfully invests in and supports cutting-edge projects with disruptive potential to rapidly translate innovation into patient-accessible therapies, through either co-development partnerships with industry or company creation. IRICoR seamlessly integrates business-related expertise with industry-level drug discovery in a world-renowned research institute, providing academics with access to a full drug discovery chain with one of the largest academia-based medicinal chemistry groups in Canada. For more information about IRICoR: iricor.ca
SOURCE Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)
For further information: For interview, please contact: Alix Molinier, Project Manager, IRICoR, 514 343-6111 #0324, [email protected]; Catherine Cardinal, Chief, Communication and Media Relations, 514 343-6111, #41299, [email protected]
Share this article